Emerging Treatment Considerations in Hepatocellular Carcinoma: An Expert Case-based Discussion

Stephen L. Chan, MD, reviews the case of a 72-year-old woman with mild alcoholic cirrhosis and provides insight on the potential role of adjuvant and neoadjuvant therapy for the treatment of HCC.

Andrea Casadei Gardini, MD, and Stephen L. Chan, MD, examine the use of TACE and TARE-Y90 for the treatment of HCC.

Gastroenterology experts discuss whether there a is a role for systemic therapy for the management of intermediate HCC.

Andrea Casadei Gardini, MD, presents the case of a 63-year-old man diagnosed with advanced HCC, and the panel reviews available first-line treatment options for patients with advanced HCC.

Experts in gastroenterology share their approaches to first-line single-agent and combination TKI therapies for the treatment of advanced HCC.

Andrea Casadei Gardini, MD, leads the discussion on the optimal sequencing of systemic therapy for advanced HCC.

A panel of experts in gastroenterology review the case of a 65-year-old man with advanced HCC associated with NASH and comment on treatment with TKIs and immunotherapy.

Stephen L. Chan, MD, leads the discussion on the prevalence and management of advanced HCC in patients with NASH.

Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.